Objective - to determine the sensitivity of Gardnerella vaginalis to
fenticonazole to justify the feasibility of using this mainly antifungal
drug for local treatment of BV in cases when it is a multifactorial disease caused by Gardnerella vaginalis and Candida spp. simultaneously.; We observed 98 women with
infections of the urogenital tract at the ages of 20 to 49. At the first stage of the study, we analyzed the results of laboratory data on pathological discharge from the urogenital system of these patients. 36 (%) of the examined women had Gardnerella vaginalis in the
vaginal discharge. At the second stage of the study, the sensitivity of Gardnerella vaginalis to
fenticonazole was determined.; The resistance to
fenticonazole was registered in 1 case (2.7%). In the remaining 35 patients Gardnerella vaginalis was not stable to
fenticonazole. High sensitivity to this substance was found in 22 of them (61.2%). Respectively, low sensitivity was registered in 13 people from the observation group (36.1%).; Gardnerella vaginalis is the main constituent and a marker of
bacterial vaginosis. The elimination of this very microorganism is of paramount importance for its treatment. In 35 studied patients (97.3%) Gardnerella vaginalis, which was isolated by culture from
vaginal discharge, had sensitivity to
fenticonazole. Moreover, in 22 of them (61.2%) the sensitivity was high, and low in 13 (36.1%). Candida spp. was found in 17 (47.1%) of 36 patients with
bacterial vaginosis. It is appropriate to use
fenticonazole as a means of local treatment during complex
therapy of women with
bacterial vaginosis that improves its compliance.